Great discussion Respert and Sherlock. Quick footnote on long acting Leronlimab: there will likely be indications/immune modulation that require a shorter pharmacological intervention window and those where a longer time window is needed. I can envision a need for both. The challenge for HIV requires a longer term carpet-bombing style CCR5 receptor blockade, likely some cancer indications might fall into that need, other indications might be over-kill. The initial half life of Alteplase as a thrombolytic for stroke is only 5 minutes…you don’t want that drug persisting forever, the need is short term and the consequences from persistence are huge.